Fragment-Based Drug Discovery – July 19-22, 2014

Fragment-Based Drug Discovery, Punta Cana.  IntelliSyn will be presenting recent results in a presentation entitled: “Extending the range of fragment methodologies:  Applications in the absence of crystallography”. 

Mastering Medicinal Chemistry – May 21-23, 2014

Mastering Medicinal Chemistry, Boston, Massachusetts.  IntelliSyn will present on the following: “Development of highly potent, selective BET bromodomain inhibitors that are CNS penetrant and effective in rodent models of brain cancer.”

IntelliSyn Achieves Milestone and Partners Cancer Project

April 1, 2014 – IntelliSyn successfully reaches its milestone with Epigenetix and partners its BRD4 inhibitor project with the NeoMed Institute to advance to clinical trials.  http://www.neomed.ca/images/pdf/NEOMED_Epigenetix_April1_En.pdf

IntelliSyn expands to new facilities at the NeoMed Institute

July 1, 2013 – IntelliSyn expands to new facilities at the NeoMed Institute the Montreal Technopark.  It is a first-tier R&D facility that has been specifically designed for early R&D work. The building is state-of-the-art  and fully equipped for chemistry, biology or drug metabolism studies.